AME Sets January 5, 2004 as Record Date for Stockholder Meeting to Vote on Proposed Merger
03 January 2004 - 2:59AM
PR Newswire (US)
AME Sets January 5, 2004 as Record Date for Stockholder Meeting to
Vote on Proposed Merger SAN DIEGO, Jan. 2 /PRNewswire-FirstCall/ --
Applied Molecular Evolution, Inc. today announced that it has
established a record date for its special stockholder meeting to
vote on the previously announced proposed merger of Genesis Merger
Sub, Inc., a wholly owned subsidiary of Eli Lilly and Company ,
into AME, pursuant to which AME would become a wholly owned
subsidiary of Lilly. AME stockholders of record at the close of
business on Monday, January 5, 2004 will be entitled to notice of
the special meeting and to vote on the proposed merger. AME will
send a definitive proxy statement/prospectus to holders of AME
common stock as of the record date. The definitive proxy
statement/prospectus will contain important information about the
proposed merger, including the date, time and location of the
special meeting of AME stockholders. AME stockholders are urged to
read the definitive proxy statement/prospectus when it becomes
available. About AME Applied Molecular Evolution, Inc. (AME) is a
leader in applying directed molecular evolution to improve
healthcare by optimizing and developing human biotherapeutics.
Directed molecular evolution is a process for optimizing genes and
proteins for specific commercial purposes. Since its inception,
AME's principal focus has been on applying its proprietary
AMEsystem(TM) technology platform to human biotherapeutics, the
largest market for directed molecular evolution. Biotherapeutics,
or biopharmaceuticals, are protein pharmaceuticals such as
antibodies, cytokines, hormones and enzymes. AME uses its
proprietary technology to develop improved versions of currently
marketed, FDA-approved biopharmaceuticals as well as novel human
biotherapeutics. For more information, please visit the Internet
website located at http://www.ame.biz/ . About Lilly Lilly, a
leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical
products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Indiana, Lilly
provides answers -- through medicines and information - for some of
the world's most urgent medical needs. Additional information about
Lilly is available at the Internet website located at
http://www.lilly.com/ . Forward Looking Statements This press
release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ
materially from those set forth in the forward looking statements,
including if the acquisition will be approved by AME's
stockholders, if the acquisition will obtain regulatory approval
under the Hart-Scott-Rodino Antitrust Improvements Act and other
regulatory approvals, whether the waiting periods for such
approvals will be extended due to requests for additional
information, whether AME will successfully complete the transaction
and those matters set forth, or incorporated by reference, in the
risk factor section of Lilly's Registration Statement on Form S-4
filed with the Securities and Exchange Commission on December 22,
2003. These forward looking statements represent AME's judgment as
of the date of this press release. AME disclaims any intent or
obligation to update these forward looking statements. Additional
Information About the Merger and Where to Find It This press
release is for informational purposes only and is not an offer to
buy or the solicitation of an offer to sell any Lilly shares, and
is not a solicitation of a proxy. In connection with the proposed
merger of a wholly owned subsidiary of Lilly with and into AME,
Lilly and AME filed a preliminary proxy statement/prospectus with
the Commission on December 22, 2003, as part of a Registration
Statement on Form S-4. Once the Registration Statement is declared
effective by the Commission, the definitive proxy
statement/prospectus will be sent to AME stockholders in connection
with the solicitation of their approval of the proposed merger.
Also, you may obtain a free copy of the Registration Statement, as
well as other documents filed by Lilly and AME with the Commission,
at the Commission's Internet website located at http://www.sec.gov/
. Investors and security holders are advised to read the definitive
proxy statement/prospectus and the Registration Statement in their
entirety because important information will be contained therein.
Once declared effective by the Commission, the Registration
Statement also will be available from Lilly by contacting Eli Lilly
and Company, Lilly Corporate Center, Indianapolis, Indiana 46285,
Attention: Shareholder Services (317) 276-6993 and from AME by
contacting Applied Molecular Evolution, Inc., 3520 Dunhill Street,
San Diego, California 92121, Attention: Investor Relations (858)
597-4990. Lilly, AME and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from AME stockholders in connection with the merger.
Information about the directors and executive officers of AME and
their interests in the merger, including their ownership of AME
stock, is set forth in the proxy statement for the 2003 annual
meeting of AME stockholders. Information about the directors and
executive officers of Lilly and their interests in the merger,
including their ownership of Lilly stock, is set forth in the proxy
statement for the 2003 annual meeting of Lilly shareholders.
Investors may obtain additional information regarding the interests
of such participants in the merger by reading the definitive proxy
statement/prospectus when it becomes available. For further
information, please contact Christopher Erdman of Applied Molecular
Evolution, +1-858-638-8635. DATASOURCE: Applied Molecular
Evolution, Inc. CONTACT: Christopher Erdman of Applied Molecular
Evolution, +1-858-638-8635 Web site: http://www.lilly.com/
http://www.ame.biz/
Copyright
Applied Molecular Evolution (NASDAQ:AMEV)
Historical Stock Chart
From May 2024 to Jun 2024
Applied Molecular Evolution (NASDAQ:AMEV)
Historical Stock Chart
From Jun 2023 to Jun 2024